TABLE 3.
Baseline characteristics (T-cell activation)
| Parameter | Responders (n = 10) | Controllers (n = 10) | PCAT (n = 11) | Noncontrollers (n = 10) |
|---|---|---|---|---|
| Age (yrs) | 43 (39-49) | 45 (41-50) | 45 (37-55) | 41 (35-48) |
| Plasma HIV RNA (log10 copies/ml) | 1.88 (1.88-1.88) | 2.00 (1.88-2.77) | 3.62 (3.43-3.91) | 4.63 (4.28-4.78) |
| CD4+ cell count (cells/mm3) | 967 (477-994) | 735 (603-1,039) | 408 (360-503) | 265 (167-323) |
| CD8+ cell count (cells/mm3) | 1,591 (1,363-2,162) | 1,040 (775-1,179) | 1,503 (1,252-2,299) | 1,300 (977-1,684) |
| CD4+ T-cell nadir (cells/mm3) | 125 (26-212) | 176 (90-190) | ||
| Duration of HIV infection (yrs) | 13 (11-13) | 15 (13-17) | 15 (14-16) | 12 (9-15) |
| Abacavir IC50a (fold change) | 6.0 (4.0-7.2) | |||
| Protease inhibitor IC50 (fold change) | 53 (17-65) | |||
| Replicative capacity (% of reference) | 27 (23-33) |
a
IC50, 50% inhibitory concentration.